Carbon monoxide released from its pharmacological donor, tricarbonyldichlororuthenium (II) dimer, accelerates the healing of pre‐existing gastric ulcers. (30th August 2017)
- Record Type:
- Journal Article
- Title:
- Carbon monoxide released from its pharmacological donor, tricarbonyldichlororuthenium (II) dimer, accelerates the healing of pre‐existing gastric ulcers. (30th August 2017)
- Main Title:
- Carbon monoxide released from its pharmacological donor, tricarbonyldichlororuthenium (II) dimer, accelerates the healing of pre‐existing gastric ulcers
- Authors:
- Magierowski, Marcin
Magierowska, Katarzyna
Hubalewska‐Mazgaj, Magdalena
Sliwowski, Zbigniew
Ginter, Grzegorz
Pajdo, Robert
Chmura, Anna
Kwiecien, Slawomir
Brzozowski, Tomasz - Abstract:
- Abstract : Background and Purpose: Carbon monoxide (CO), a gaseous mediator produced by haem oxygenases (HOs), has been shown to prevent stress‐, ethanol‐, aspirin‐ and alendronate‐induced gastric damage; however, its role in gastric ulcer healing has not been fully elucidated. We investigated whether CO released from tricarbonyldichlororuthenium (II) dimer (CORM‐2) can affect gastric ulcer healing and determined the mechanisms involved in this healing action. Experimental Approach: Gastric ulcers were induced in Wistar rats by serosal application of acetic acid. Animals received 9 days of treatment with RuCl3 [2.5 mg·kg −1 intragastrically (i.g.)], haemin (5 mg·kg −1 i.g.), CORM‐2 (0.1–10 mg·kg −1 i.g.) administered alone or with zinc protoporphyrin IX (ZnPP, 10 mg·kg −1 i.g.), 1H‐[1, 2, 4]oxadiazolo[4, 3‐a]quinoxalin‐1‐one (ODQ, 5 mg·kg −1 i.g.), N G ‐nitro‐l ‐arginine (l ‐NNA, 15 mg·kg −1 i.g.), indomethacin (5 mg·kg −1 i.g.) or glibenclamide (10 mg·kg −1 i.g.). Gastric ulcer area and gastric blood flow (GBF) were assessed planimetrically, microscopically and by laser flowmeter respectively. Gastric mRNA/protein expressions of EGF, EGF receptors, VEGFA, HOs, nuclear factor (erythroid‐derived 2)‐like 2 (Nrf2), COX‐2, hypoxia‐inducible factor (HIF)‐1α and pro‐inflammatory iNOS, IL‐1β and TNF‐α were determined by real‐time PCR or Western blots. Key Results: CORM‐2 and haemin but not RuCl3 or ZnPP decreased ulcer size while increasing GBF. These effects were reduced by ODQ,Abstract : Background and Purpose: Carbon monoxide (CO), a gaseous mediator produced by haem oxygenases (HOs), has been shown to prevent stress‐, ethanol‐, aspirin‐ and alendronate‐induced gastric damage; however, its role in gastric ulcer healing has not been fully elucidated. We investigated whether CO released from tricarbonyldichlororuthenium (II) dimer (CORM‐2) can affect gastric ulcer healing and determined the mechanisms involved in this healing action. Experimental Approach: Gastric ulcers were induced in Wistar rats by serosal application of acetic acid. Animals received 9 days of treatment with RuCl3 [2.5 mg·kg −1 intragastrically (i.g.)], haemin (5 mg·kg −1 i.g.), CORM‐2 (0.1–10 mg·kg −1 i.g.) administered alone or with zinc protoporphyrin IX (ZnPP, 10 mg·kg −1 i.g.), 1H‐[1, 2, 4]oxadiazolo[4, 3‐a]quinoxalin‐1‐one (ODQ, 5 mg·kg −1 i.g.), N G ‐nitro‐l ‐arginine (l ‐NNA, 15 mg·kg −1 i.g.), indomethacin (5 mg·kg −1 i.g.) or glibenclamide (10 mg·kg −1 i.g.). Gastric ulcer area and gastric blood flow (GBF) were assessed planimetrically, microscopically and by laser flowmeter respectively. Gastric mRNA/protein expressions of EGF, EGF receptors, VEGFA, HOs, nuclear factor (erythroid‐derived 2)‐like 2 (Nrf2), COX‐2, hypoxia‐inducible factor (HIF)‐1α and pro‐inflammatory iNOS, IL‐1β and TNF‐α were determined by real‐time PCR or Western blots. Key Results: CORM‐2 and haemin but not RuCl3 or ZnPP decreased ulcer size while increasing GBF. These effects were reduced by ODQ, indomethacin, l ‐NNA and glibenclamide. CORM‐2 significantly decreased the expression of pro‐inflammatory markers, Nrf2/HO1 and HIF‐1α, and up‐regulated EGF. Conclusions and Implications: CO released from CORM‐2 or endogenously produced by the HO1/Nrf2 pathway accelerates gastric ulcer healing via an increase in GBF, an up‐regulation in EGF expression and down‐regulation of the inflammatory response. … (more)
- Is Part Of:
- British journal of pharmacology. Volume 174:Number 20(2017)
- Journal:
- British journal of pharmacology
- Issue:
- Volume 174:Number 20(2017)
- Issue Display:
- Volume 174, Issue 20 (2017)
- Year:
- 2017
- Volume:
- 174
- Issue:
- 20
- Issue Sort Value:
- 2017-0174-0020-0000
- Page Start:
- 3654
- Page End:
- 3668
- Publication Date:
- 2017-08-30
- Subjects:
- Pharmacology -- Periodicals
Chemotherapy -- Periodicals
Drug Therapy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://bibpurl.oclc.org/web/21844 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381/issues ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=282&action=archive ↗
http://onlinelibrary.wiley.com/ ↗
http://www.nature.com/bjp/index.html ↗ - DOI:
- 10.1111/bph.13968 ↗
- Languages:
- English
- ISSNs:
- 0007-1188
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2314.700000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 8548.xml